Medindia

X

Reportlinker Adds The Future of Enteral Nutrition: Key players, Disease Specific Opportunities and Market Forecasts

Wednesday, August 25, 2010 General News J E 4
Advertisement
NEW YORK, Aug. 25 Reportlinker.com announces that a new market research report is available in its catalogue:

The Future Of Enteral Nutrition: Key players, disease specific opportunities and market forecasts

http://www.reportlinker.com/p0284297/The-Future-Of-Enteral-Nutrition-Key-players-disease-specific-opportunities-and-market-forecasts.html

Fuelled by an aging population and rising rates of illness, the clinical nutrition markets in the US, Canada and the EU continue to expand. Each of the five major product manufacturers are attempting to differentiate their offerings through the development of new products tailored specifically for certain patient groups. These products offer significantly greater nutritive benefits than more general products, offering manufacturers a means to establish leadership in these segments and capture share. Certain other companies, including start up enterprises, are also entering this market with unique new products.

This report analyzes the clinical nutrition market, identifying new product opportunities, and discusses how they will impact the market in the near and long term. The product development strategies of the leading manufacturers are analyzed and key opportunities are identified.

Key features of this report

Scope of this report

Key Market Issues

Key findings from this report

Key questions answered

Table of Contents

Executive summary 9

Introduction 9

Enteral nutrition in the US and Canada 10

Enteral nutrition in the EU 11

Opportunities in enteral nutrition 12

Chapter 1 Introduction 13

Summary 13

Introduction 14

Disease populations for enteral nutrition 15

Cancer patients 17

Enteral nutrition for cancer patients 19

Patients with neuromuscular conditions 20

Enteral nutrition for patients with neuromuscular conditions 21

Gastrointestinal disease patients 21

Enteral nutrition for GI disease patients 23

Malnutrition patients 24

Enteral nutrition for malnutrition patients 25

Other clinical nutrition patients 25

Alzheimer's disease sufferers 25

Anorexia nervosa patients 26

Burn patients 26

The critically ill 27

Dialysis patients 28

Immunotherapy/AIDS patients 28

Respiratory patients 30

Surgery and/or transplantation patients 30

Special populations for enteral nutrition 31

Diabetics 31

The obese 32

Seniors 32

Environments for enteral nutrition 32

Inpatient environments 33

Outpatient environments 34

Major types of enteral nutrition 35

Enteral vs. parenteral nutrition 35

Oral vs. tube feeding 36

Nasal intubation 36

Surgical insertion of feeding tubes 37

Products and ingredients 39

Related products 41

Market summary 44

Chapter 2 Enteral nutrition in the US and Canada 48

Summary 48

Introduction 49

Regulation 49

Insurance reimbursement 51

User populations 54

Enteral nutrition in the US 55

Key products and players 55

Sales and market share, 2009-2014 57

Sales by disease population 59

New product development 60

Opportunities 61

Near term (2010-2012) 61

Long term (2013-2014) 64

Enteral nutrition in Canada 65

Key products and players 66

Sales and market share, 2009-2014 67

Sales by disease population 68

New product development 69

Opportunities 70

Near term (2010-2012) 70

Long term (2013-2014) 70

Conclusions 71

Chapter 3 Enteral nutrition in the EU 72

Summary 72

Introduction 73

Regulation 73

Insurance reimbursement 73

User populations 74

Enteral nutrition in the EU 75

Key products and players 75

Sales and market share, 2009-2014 82

Germany 84

France 85

UK 86

Italy 88

Spain 89

Poland 90

Sales by disease population 91

Germany 92

France 94

UK 94

Italy 95

Spain 96

Poland 96

New product development 97

Opportunities 97

Near term (2010-2012) 97

Long term (2013-2014) 99

Conclusions 102

Chapter 4 Opportunities in enteral nutrition 103

Summary 103

Introduction 104

New products and other opportunities by disease population 104

Cancer 105

Critical illness 106

Diabetes 107

Dysphagia 108

Gastrointestinal disease 108

Liver failure 109

Kidney disease 109

Obesity 110

Respiratory conditions 110

Other conditions 111

Product development strategies of leading enteral nutrition players 111

Abbott Nutrition 112

B. Braun 113

Danone Baby and Medical Nutrition 114

Fresenius Kabi 115

Nestle HealthCare Nutrition 116

Conclusions 117

Appendix 118

Scope 118

Methodology 118

Abbreviations 118

Table of figures

Figure 1: Key nutritive needs by condition 16

Figure 2: Enteral nutrition patients ('000) in the US, Canada and the EU, 2009-2014 44

Figure 3: Sales of enteral nutrition products ($m) in the US, Canada and the EU, 45

Figure 4: Sales of enteral nutrition products ($m) in the US, Canada and the EU by disease population, 2009 - 2014 46

Figure 5: Sales of enteral nutrition products ($m) in the US, Canada and the EU by major manufacturer, 2009 47

Figure 6: Number of enteral nutrition patients ('000) in the US and Canada, 2009 - 2014 54

Figure 7: Total US enteral nutrition market ($m), 2009-2014 58

Figure 8: Leading US enteral nutrition players, 2009 59

Figure 9: US enteral nutrition market ($m) by disease population, 2009-2014 60

Figure 10: Total Canadian enteral nutrition market ($m), 2009-2014 67

Figure 11: Leading Canadian enteral nutrition players, 2009 68

Figure 12: Canadian enteral nutrition market ($m) by disease population, 2009-2014 69

Figure 13: Number of EU enteral nutrition patients ('000), 2009-2014 74

Figure 14: EU country potential for enteral nutrition, 2010 80

Figure 15: Malnutrition in the EU by country, 2010 81

Figure 16: Total EU enteral nutrition market ($m), 2009-2014 82

Figure 17: Leading EU enteral nutrition players, 2009 84

Figure 18: German enteral nutrition market and patients, 2009-2014 85

Figure 19: French enteral nutrition market and patients, 2009-2014 86

Figure 20: UK enteral nutrition market and patients, 2009-2014 87

Figure 21: Italian enteral nutrition market and patients, 2009-2014 89

Figure 22: Spanish enteral nutrition market and patients, 2009-2014 90

Figure 23: Polish enteral nutrition market and patients, 2009-2014 91

Figure 24: EU enteral nutrition market ($m) by disease population, 2009-2014 92

Figure 25: EU hospital stays vs. home care patients, 1990-2010 100

Figure 26: Enteral nutrition opportunities by disease population, 2010 105

Figure 27: Strategy and product development activities of leading enteral nutrition product manufacturers, 2010 112

Table of tables

Table 1: Inpatient care facilities in the US, Canada and the EU, 2009 33

Table 2: Advantages and disadvantages of feeding routes and types 39

Table 3: Disease specific enteral nutrition products 43

Table 4: US FDA definition of medical food 51

Table 4: US Medicare reimbursement for enteral nutrition products, 2009 53

Table 5: Leading US enteral nutrition products, 2010 56

Table 6: Leading US enteral nutrition products, 2010 (ctd1) 57

Table 7: Leading Canadian enteral nutrition products, 2010 66

Table 8: Leading EU enteral nutrition products, 2010 76

Table 9: Demographic data for EU member countries 2006 78

Table 10: Healthcare data for EU member countries 2006 79

To order this report:

Drug Delivery Technology Industry: The Future Of Enteral Nutrition: Key players, disease specific opportunities and market forecasts

Drug Delivery Technology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

-- Examines the current products and uses for clinical nutrition -- Identifies and analyzes the most recent trends and issues in enteral nutrition -- Forecasts the market through 2014 for the US, Canada and EU as well as by major European country, including market share information and size/growth forecasts -- Discusses how different market segments will evolve over the next five years and why -- Explores the complexities of market trends and opportunities -- Profiles the major enteral nutrition companies and their growth strategies

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds US Infectious Disease Testing Ma...
S
Reportlinker Adds US Clinical Chemistry And Immuno...